Pharma Mar (OTCMKTS:PHMMF) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Pharma Mar (OTCMKTS:PHMMF) to a hold rating in a report released on Monday,Zacks.com reports.

PHMMF has been the topic of a number of other reports. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. BTIG Research assumed coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They issued a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

Pharma Mar Price Performance

Pharma Mar stock opened at $79.49 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 1-year low of $77.41 and a 1-year high of $110.40. The company’s 50-day moving average is $104.27 and its 200 day moving average is $94.45.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.